Nonadherence in outpatient thromboprophylaxis after major orthopedic surgery: A systematic review

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 10, Issue 6, 2010, Pages 691-700

  Wilke, Thomas ^a   Müller, Sabrina ^a  

^a Hochschule Wismar   (Germany)

Author keywords

adherence; heparins; LMWH; low molecular weight herapin; major orthopedic surgeries; nonadherence; noncompliance; outpatient thromboprophylaxis

Indexed keywords

ANTICOAGULANT AGENT; DABIGATRAN ETEXILATE; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; ATTITUDE TO ILLNESS; FEAR; GERMANY; HIP ARTHROPLASTY; HOSPITALIZATION; HUMAN; KNEE ARTHROPLASTY; MAJOR SURGERY; MEDICAL LITERATURE; ORTHOPEDIC SURGERY; OUTPATIENT CARE; PATIENT ATTITUDE; PATIENT CARE; PRACTICE GUIDELINE; PUBLICATION; REHABILITATION CARE; REVIEW; SYSTEMATIC REVIEW; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT REFUSAL;

AMBULATORY CARE; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; HUMANS; MEDICATION ADHERENCE; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES AS TOPIC; THROMBOSIS;

EID: 78650503225     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.10.77     Document Type: Review

References (50)

1. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomized trials. Lancet 358, 9-15 (2001).
2. Hull RD, Pineo GF, Stein PD et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann. Intern. Med. 135(10), 858-869 (2001).
3. Kolb G, Bodamer I, Galster H et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thromb. Haemost. 90(6), 1100-1105 (2003).
4. Kakkar AK, Brenner B, Dahl OE et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372(9632), 31-39 (2008).
5. Geerts WH, Bergqvist DF, Pineo G et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133, 381-453 (2008).
6. Haentjens P, De Groote K, Annemans L. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis. Arch. Orthop. Trauma Surg. 124(8), 507-517 (2004).
7. Bischof M, Leuppi JD, Sendi P. Cost-effectiveness of extended venous thromboembolism prophylaxis with fondaparinux in hip surgery patients. Expert Rev. Pharmacoecon. Outcomes Res. 6(2), 171-180 (2006).
8. Skedgel C, Goeree R, Pleasance S, Thompson K, O'Brien B, Anderson D. The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty. J. Bone Joint Surg. Am. 89(4), 819-828 (2007).
9. Huo MH, Muntz J. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review. Clin. Ther. 31(6), 1129-1141 (2009).
10. Amin AN, Lin J, Ryan A. Need to improve thromboprophylaxis across the continuum of care for surgical patients. Adv. Ther. 27(2), 81-93 (2010).
11. Borris LC. Barriers to the optimal use of anticoagulants after orthopaedic surgery. Arch. Orthop. Trauma Surg. 129(11), 1441-1445 (2009).
12. Eriksson BI, Dahl OE, Rosencher N et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J. Thromb. Haemost. 11, 2178-2185 (2007). (Pubitemid 47617868)
13. Eriksson BI, Kakkar AK, Turpie AG et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J. Bone Joint Surg. Br. 91(5), 636-644 (2009).
14. Friedman RJ, Dahl OE, Rosencher N et al. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb. Res. 126(3), 175-182 (2010).
15. Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty: a meta-analysis. Thromb. Haemost. 101, 77-85 (2009).
16. Wolowacz SE, Roskell NS, Maciver F et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin. Ther. 31(1), 194-212 (2009).
17. Wilke T. Patient preferences for an oral anticoagulant after major orthopaedic surgery: results of a German survey. Patient 2, 39-49 (2009).
18. OECD Health Data. Average Length of Stay by Diagnostic Categories (CD-Rom). OECD Publishing, Paris, France (2009).
19. Wilke T, Moock J, Muller S, Pfannkuche M, Kurth A. Nonadherence in outpatient thrombosis prophylaxis with low molecular weight heparins after major orthopaedic surgery. Clin. Orthop. Relat. Res. 468(9), 2437-2453 (2010).
20. Osterberg L, Blaschke T. Adherence to medication. N. Engl. J. Med. 353, 487-497 (2005).
21. Liu H, Miller HG, Hays RD et al. A comprehensive evaluation of survey questions for adherence to antiretroviral medications and exploratory analyses for identifying optimal sets of survey questions. AIDS Patient Care STDS 20, 760-772 (2006).
22. Karve S, Cleves MA, Helm M, Hudson TJ, West D, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr. Med. Res. Opin. 25(9), 2303-2310 (2009).
23. Bjornara BT, Gudmundsen TE, Dahl OE. Frequency and timing of clinical venous thromboembolism after major joint surgery. J. Bone Joint Surg. Br. 88, 386-391 (2006).
24. Arcelus JI, Kudrna JC, Caprini JA. Venous thromboembolism following major orthopaedic surgery: what is the risk after discharge? Orthopaedics 29(6), 506-516 (2006).
25. Watts AC, Howie CR, Simpson AH. Assessment of a self-administration protocol for extended subcutaneous thromboprophylaxis in lower limb arthroplasty. J. Bone Joint Surg. Br. 88(1), 107-110 (2006).
26. Karlinski M, Stolarczyk A, Siuda M, Ziolkowski M. Compliance with low molecular weight heparin in ambulatory orthopaedic patients. Ortop. Traumatol. Rehabil. 8, 633-638 (2006).
27. Spahn G. Compliance with self-administration of heparin injections in outpatients. Eur. J. Trauma 28(2), 104-109 (2002).
28. Le Gall C, Jacques E, Medjebeur C et al. Low molecular weight heparin self-injection training: assessment of feasibility, tolerance and economic analysis in emergency departments. Eur. J. Emerg. Med. 13, 264-269 (2006).
29. Colwell CW Jr, Pulido P, Hardwick ME, Morris BA. Patient compliance with outpatient prophylaxis: an observational study. Orthopaedics 28, 143-147 (2005).
30. Peterson AM, Nau D, Cramer JA, Benner J, Gwadry-Sridhar F, Nichal M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 10(1), 3-12 (2007).
31. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst. Rev. (2), CD000011 (2008).
32. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of Type 2 diabetic patients. J. Int. Med. Res. 30, 71-79 (2002).
33. Friedman RJ, Gallus AS, Cushner FD, Fitzgerald G, Anderson FA Jr; Global Orthopaedic Registry Investigators. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr. Med. Res. Opin. 24, 87-97 (2008).
34. Eikelboom JW, Karthikeyan G, Fagel N, Hirsh J. American Association of Orthopaedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients? Chest 135(2), 513-520 (2009).
35. Le Sage S, McGee M, Emed JD. Knowledge of venous thromboembolism (VTE) prevention among hospitalized patients. J. Vasc. Nurs. 26(4), 109-117 (2008).
36. Marks JR, Schectman JM, Groninger H, Plews-Ogan ML. The association of health literacy and socio-demographic factors with medication knowledge. Patient Educ. Couns. 78(3), 372-376 (2010).
37. Gazmararian JA, Kripalani S, Miller MJ, Echt KV, Ren J, Rask K. Factors associated with medication refill adherence in cardiovascular-related diseases: a focus on health literacy. J. Gen. Intern. Med. 21(12), 1215-1221 (2006).
38. Kistler U, Kramers-de Quervain I, Munzinger U, Kucher N. Bleeding complications after systematic switch of routine thromboprophylaxis for major orthopaedic surgery. Thromb. Haemost. 99(6), 1049-1052 (2008).
39. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med. Care 24(1), 67-74 (1986).
40. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J. Clin. Hypertens. (Greenwich) 10, 348-354 (2008).
41. Mahler C, Hermann K, Horne R et al. Assessing reported adherence to pharmacological treatment recommendations. Translation and evaluation of the Medication Adherence Report Scale (MARS) in Germany. J. Eval. Clin. Pract. 16(3), 574-579 (2010).
42. Kim MT, Hill MN, Bone LR, Levine DM. Development and testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale. Prog. Cardiovasc. Nurs. 15(3), 90-96 (2000).
43. Kripalani S, Risser J, Gatti ME, Jacobson TA. Development and evaluation of the Adherence to Refills and Medications Scale (ARMS) among low-literacy patients with chronic disease. Value Health 12(1), 118-123 (2009).
44. Hahn SR, Park J, Skinner EP et al. Development of the ASK-20 adherence barrier survey. Curr. Med. Res. Opin. 24(7), 2127-2138 (2008).
45. Byerly MJ, Nakonezny PA, Rush AJ. The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder. Schizophr. Res. 100(1-3), 60-69 (2008).
46. Rofail D, Abetz L, Viala M, Gait C, Baladi JF, Payne K. Satisfaction and adherence in patients with iron overload receiving iron chelation therapy as assessed by a newly developed patient instrument. Value Health 12(1), 109-117 (2009).
47. Chisholm MA, Lance CE, Williamson GM, Mulloy LL. Development and validation of the immunosuppressant therapy adherence instrument (ITAS). Patient Educ. Couns. 59(1), 13-20 (2005).
48. Rolley JX, Davidson PM, Dennison CR, Ong A, Everett B, Salamonson Y. Medication adherence self-reported instruments: implications for practice and research. J. Cardiovasc. Nurs. 23, 497-505 (2008).
49. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol. Drug Saf. 15, 565-574 (2006).
50. Horne R, Weinman J, Barber N, Elliott R, Morgan M. Concordance, adherence and compliance in medicine taking. Report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R & D (2005) www. medslearning. leeds.ac.u k/ pages/documents/useful-docs/76-final-report%5B1%5D.pdf